Advanced Cell Technology Inc. (ACT) is about to deliver good news from its Phase I/II trials of retinal pigmented epithelial (RPE) cells and perk up the prospects for human embryonic stem cell (hESC)-based therapies following Geron Inc.'s abrupt withdrawal from the field last week.